



Date: 26th May, 2023

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Subject: Outcome of the Board Meeting of Nidan Laboratories and Healthcare Limited held on Friday, 26th May, 2023.

Reference: NSE Symbol - NIDAN

Madam / Sir,

This is to inform you that pursuant to Regulation 30 & Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and other applicable provisions, the Board of Directors of the Company at its meeting held today have:

1. Approved the Audited Financial Results of the Company for the year ended 31st March, 2023;
2. Taken on record the Audit Report by the Statutory Auditors of the Company for the aforesaid results;

Unmodified Opinion:

Further, this is hereby declared that M/s R. K. Chapawat & Co., Chartered Accountants, the Statutory Auditors of the Company, have issued Auditors' Report with an unmodified opinion on the Audited Financial Statements for the financial year ended March 31, 2023. This declaration is made pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

AKSHAY
ARUN
JOSHI

Digitally signed by
AKSHAY ARUN
JOSHI
Date: 2023.05.26
14:52:03 +05'30'





In view of the above, we hereby enclose the following:

1. Audited Financial Results in respect of Nidan Laboratories and Healthcare Limited for the year ended 31st March, 2023.
2. Statutory Auditor's Report on Audited financial results of Nidan Laboratories and Healthcare Limited for the year ended 31st March, 2023.
3. A declaration with respect to Audit Report with unmodified opinion to the audited financial results.

The meeting of the Board of Directors of the Company commenced at 2.00 PM and concluded at 2.50 p.m.

This is for your information and records.

For Nidan Laboratories and Healthcare Limited

AKSHA
Y ARUN
JOSHI

Digitally signed
by AKSHAY
ARUN JOSHI
Date:
2023.05.26
14:52:27 +05'30'

Akshay Joshi

Company Secretary & Compliance Officer

ACS: 34724





Date: 26th May, 2023

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Subject: Declaration w.r.t Audit Report with unmodified opinion on the Audited Financial results for the financial year ended 31st March, 2023.

Reference: NSE Symbol - NIDAN

Madam / Sir,

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby declares that M/s R. K. Chapawat & Co., Chartered Accountants, the Statutory Auditors of the Company have issued their Audit Report on the Audited Financial Results of the Company for the financial year ended 31st March, 2023 with unmodified opinion.

This is for your information and records.

For Nidan Laboratories and Healthcare Limited

Digitally signed
by Tejal Anil
Jayakar
Date: 2023.05.26
14:53:27 +05'30'

Tejal Anil Jayakar
Director
DIN: 07984686



Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (w), 401303

Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Statement of Audited Financial Results for the half and year Ended on 31st March 2023

	Particulars	Half Year ended (Rs in lakhs)			Year Ended (Rs in lakhs)	
		31-Mar-23	30-Sep-22	31-Mar-22	31-Mar-23	31-Mar-22
		Audited	Unaudited	Audited	Audited	Audited
1	Income					
	a) Revenue from Operations	1,017.73	1,408.86	1,313.80	2,426.59	2,966.01
	b) Other Income	300.28	32.65	38.99	332.93	40.22
	Total Income (a+b)	1,318.01	1,441.51	1,352.80	2,759.52	3,006.24
2	Expenses					
	a) Cost of Materials Consumed	53.81	70.03	118.38	123.84	319.92
	b) Changes in inventories of Finished Goods, Work in Progress and Stock-in-Trade	(14.15)	(0.78)	3.70	(14.94)	(11.00)
	c) Employee benefit expenses	284.81	215.07	210.68	499.88	367.52
	d) Finance Costs	119.07	103.24	94.61	222.31	266.48
	e) Depreciation and Amortization expenses	166.14	143.68	87.14	309.82	263.08
	f) Other Expenses	529.35	608.09	618.97	1,137.45	1,348.19
	Total Expenses (a to g)	1,139.03	1,139.33	1,133.49	2,278.36	2,554.20
3	Profit before tax	178.98	302.18	219.31	481.16	452.04
4	Tax Expenses					
	a) Current Tax	39.49	90.65	79.64	130.14	132.00
	b) Deferred Tax Asset/Liability	17.35	(20.29)	(20.29)	(2.94)	(20.29)
	c) Tax of earlier year	-	-	74.04	-	74.04
	Total tax expenses	56.84	70.36	133.39	127.20	185.75
5	Profit for the period	122.14	231.82	85.92	353.96	266.29
6	Paid-up equity share capital (Face value of Rs 10/- per share)	1,390.00	1,390.00	1,390.00	1,390.00	1,390.00
7	Earnings Per Share (not annualised)					
	a) Basic EPS	0.88	1.67	0.62	2.55	2.32
	b) Diluted EPS	0.88	1.67	0.62	2.55	2.32

Notes:

- The audited financial results have been reviewed by Audit Committee and approved by Board of Directors in their respective meetings held on 26 th May , 2023
- The equity shares of the company are listed on SME Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure requirements) Regulations, 2009 and hence exempted from Compulsary adoption of Ind AS for the preparation of Financial statements vide Notification dated 16th February ,2015 issued by ministry of corporate affairs.
- The Company does not have different segments and hence segment wise reporting is not applicable to the Company.
- The figures of the corresponding previous half year /year have been regrouped/rearranged wherever considered necessary to make them comparable


For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited



Tejal Anil Jayakar
Executive Director
DIN:07984686

Date : 26th May 2023
Place : Virar

Nidan Laboratories And Healthcare Limited
Statement of Assets & Liabilities as at 31st march 2023

		Rs in lakhs	
	Particulars	As at March 31, 2023 (Audited)	As at March 31, 2022 (Audited)
I	Equity & Liabilities		
	1. Shareholders' funds		
	Equity Share Capital	1,390.00	1,390.00
	Reserves and Surplus	5,553.84	5,199.89
		6,943.84	6,589.89
	2. Non - Current Liabilities		
	(a) Long - Term Borrowings	477.49	941.74
	(b) Other Long term liabilities	16.74	34.04
	(c) Long Term Provisions	47.61	3.93
		541.84	979.71
	3. Current Liabilities		
	(a) Short - Term Borrowings	615.50	987.73
	(b) Trade Payables		
	(i) Total outstanding due of micro enterprises and small enterprises; and	-	-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	20.60	114.87
	(c) Other Current Liabilities	53.80	47.08
	(d) Short - Term Provisions	264.58	128.62
		954.48	1,278.30
	TOTAL	8,440.16	8,847.90
II	Assets		
	1. Non - Current Assets		
	(a) Property Plant & Equipment and Intangible Assets		
	(i) Property, Plant & Equipments	2,136.62	2,044.79
	(ii) Intangible Asset	2.64	1.20
	(ii) Capital workin progress	-	381.36
	(b) Non-Current Investments	-	-
	(c) Long - Term Loans and Advances	4,076.05	3,771.90
	(d) Deferred Tax Asset (Net)	48.30	45.37
	(e) Other Non Current Assets	88.44	72.96
		6,352.05	6,317.58
	2. Current Assets		
	(a) Inventories	36.52	21.58
	(b) Trade Receivables	602.61	536.17
	(c) Cash and Cash Equivalents	841.94	810.14
	(d) Short - Term Loans and Advances	336.18	910.07
	(e) Other Current Assets	270.86	252.36
		2,088.11	2,530.32
	TOTAL	8,440.16	8,847.90
		For and on behalf of Board of Directors Nidan Laboratories and Healthcare Limited	
		  Tejal Anil Jayakar Executive Director DIN:07984686	
Date : 26th May 2023 Place : Virar			

Nidan Laboratories And Healthcare Limited
Statement of Cash flow for the year ended 31st March 2023

Rs in lakhs

Particulars	For the year ended March 31, 2023	For the year ended March 31, 2022
A - CASH FLOW FROM OPERATING ACTIVITIES		
Restated Profit Before Tax	481.16	452.04
Add/ (less) Adjustment for:		
Interest Income	-	(0.53)
Interest Expenses	222.31	243.53
Depreciation	309.82	263.08
Sundry Balance Written back	-	(23.63)
(Gain)/loss on disposal of property, plant and equipment	(26.90)	(28.90)
Operating Profit Before Working Capital Changes	986.39	905.59
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	(66.44)	7.02
(Increase)/ decrease in Other Current Assets	(18.49)	3.98
(Increase) / decrease in Short Term Loans and Advances	573.89	(55.60)
(Increase) / decrease in Other Non current assets	(15.48)	12.55
(Increase) / decrease in Inventories	(14.94)	(11.00)
Increase / (decrease) in Trade payables	(94.26)	(14.03)
Increase / (decrease) in Long term liability	(17.30)	27.50
Increase / (decrease) in Other current Liability	6.71	16.28
Increase / (decrease) in Short Term Provision	135.96	2.70
Increase / (decrease) in Long term Provisions	43.68	3.93
Cash Generated from Operations	1,519.72	898.92
Add/ (less) : Direct taxes paid (net of refund received)	(130.14)	(116.17)
Net Cash inflow from Operating Activities	1,389.58	782.76
B - CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment / intangible assets	(66.83)	(707.44)
Proceeds from sale of property, plant and equipment	72.00	59.62
(Increase) / Decrease in Long term loans and advances	(304.15)	(2,926.89)
Interest received	-	0.53
Net cash inlow/(outflow) from investing activities	(298.98)	(3,574.19)
C - CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (repayment) of borrowings (net)	(836.49)	(1,875.08)
Proceeds from issue of shares (net)	-	4,990.50
Interest Expenses	(222.31)	(243.53)
Net Cash inflow/(outflow) flow from Financing Activities	(1,058.80)	2,872
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	31.80	80.46
Add: Cash and Cash Equivalents at the beginning of the year	810.14	729.67
Cash and Cash Equivalents at the end of the period/year	841.94	810.14
Notes :		
Cash and Cash Equivalents at the end of the year consists of cash in hand and balances with banks are as follows :		
Particulars	As at March 31, 2023	As at March 31, 2022
Cash on hand	823.20	770.28
Balances with bank	18.74	39.85
Cash and Cash Equivalents	841.94	810.14
Date : 26th May 2023 Place : Virar  For and on behalf of the Board of Directors Nidan Laboratories And Healthcare Limited <i>(Signature)</i> Tejal Jaykar Director & CFO DIN: 07984686		

Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,

Vartak Road, Virar (w), 401303

Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in

Statement Of Financial Results For The Half And Year Ended 31st March 2023

Rs in lakhs

S.No.	Particulars	Half Year Ended 31st March	Half Year Ended 30th Sept 2022	Half Year Ended 31st March 2022	Year Ended 31st March, 2023	Year Ended 31st March, 2022
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	1318.01	1441.51	1352.80	2759.52	3006.24
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	178.98	302.18	219.31	481.16	452.04
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	178.98	302.18	219.31	481.16	452.04
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	122.14	231.82	85.92	353.96	266.29
5	Total Comprehensive income for the period [comprising Profit for the period (after tax) and other comprehensive Income (after tax)]	122.14	231.82	85.92	353.96	266.29
6	Paid up Equity Share Capital	1390.00	1390.00	1390.00	1390.00	1390.00
7	Reserves (exluding revaluation reserve)	51.77	5502.07	4676.42	5,553.84	5199.89
8	Earnings Per Share (of Rs 10/-each) (for continuing and discontinued operations)					
	Basic	0.88	1.67	0.62	2.55	2.32
	Diluted	0.88	1.67	0.62	2.55	2.32

1) The above is an extract of the detailed format of Annual Financial Results to filed with National Stock Exchange Limited under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited



Tejal Anil Jayakar
Executive Director
DIN:07984686

Date : 26th May 2023

Place : Virar



R. K. GHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Office : 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West) Dist - Palghar : 401303.
Contact : +91-9323791318 / 0250-2513406, **E-mail :** ravindra_chapawat@rediffmail.com

Independent Auditor's Report on the Annual Audited Financial Results of Nidan Laboratories and HealthCare Limited for the half-year and year ended 31st March, 2023 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Amended)

To,
The Board of Directors of
Nidan Laboratories and HealthCare Limited

Opinion

We have audited the accompanying financial results of Nidan Laboratories and HealthCare Limited ("the Company") for the half year ended 31st March, 2023 and the year-to-date results for the period from 1st April 2022 to 31st March, 2023, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year ended 31st March, 2023 and the year-to-date results for the period from 1st April, 2022 to 31st March, 2023.

Basic for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Financial Results

The statement which is the responsibility of the company's management and approved by the board of directors, has been prepared on the basis of financial statement. The company's Board of Directors are responsible for the preparation of these financial results that give true and fair view of the net profit and other financial information in accordance with the Accounting Standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material

Misstatement resulting from fraud is higher, than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures

That are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in due financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in the manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the half year ended March 31, 2023 being the balancing figure between audited figures in respect of the full financial year and the unaudited years to date figures up to the Half year (September 30, 2022) of the current financial year which were subject to limited review by us. Report or the Statement is not modified in respect of this matter.

For R. K. Chapawat & Co.
Chartered Accountants
Firm Registration no. 101708W

Purnima

Purnima Jain
Partner
Membership No.: 140032
Udin No.: 23140032BGZUDE6895
Place: Virar
Date: 26th May 2023

